Structure Therapeutics: Positive Oral Weight Loss Drug Clinical Data

Structure Therapeutics reported positive Phase 1/2a clinical data for ACCG-2671, an oral small molecule amylin receptor agonist showing a 3.3% body weight reduction and good safety profile, and positive 72-week data for aleniglipron, an oral GLP-1 receptor agonist, with up to 16.2% weight loss and good tolerability. Phase 3 trials for aleniglipron are ongoing with topline data expected in 2H 2028.

This Wire brief sits within Fusion42's coverage of Health.